The study protocol: Neuroendocrinology and (epi-) genetics of female reproductive transition phase mood disorder - an observational, longitudinal study from pregnancy to postpartum by Johann, Alexandra & Ehlert, Ulrike








The study protocol: Neuroendocrinology and (epi-) genetics of female
reproductive transition phase mood disorder - an observational, longitudinal
study from pregnancy to postpartum
Johann, Alexandra ; Ehlert, Ulrike
Abstract: BACKGROUND: Postpartum depression is considered to be one of the most common health
threats during pregnancy and postpartum, affecting not only the woman herself but also the offspring
and the whole family system. Evidence for a conclusive etiopathological model with distinct risk and
resilience factors is still broadly lacking. Therefore, the aim of the present study is to investigate numerous
health-related markers to obtain greater insight into which biopsychosocial profiles render women more
vulnerable to PPD or facilitate a healthy transition from pregnancy to postpartum. METHODS: The
observational, longitudinal study aims to include a total of 288 physically healthy women, aged 20-
45 years. A multitude of relevant parameters, of an (epi-) genetic, endocrinological, physiological and
psychological nature, will be assessed over a period of 5 months, following the participants from the 3rd
trimester until three months postpartum. DISCUSSION: The ultimate goal of the present study is to
ameliorate mental health care during pregnancy and postpartum, by gaining a better understanding of
the underlying biopsychosocial mechanisms that women undergo during the transition from pregnancy
to postpartum.
DOI: https://doi.org/10.1186/s12884-020-03280-5






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Johann, Alexandra; Ehlert, Ulrike (2020). The study protocol: Neuroendocrinology and (epi-) genetics of
female reproductive transition phase mood disorder - an observational, longitudinal study from pregnancy
to postpartum. BMC Pregnancy and Childbirth, 20(1):609.
DOI: https://doi.org/10.1186/s12884-020-03280-5
STUDY PROTOCOL Open Access
The study protocol: Neuroendocrinology
and (epi-) genetics of female reproductive
transition phase mood disorder - an
observational, longitudinal study from
pregnancy to postpartum
Alexandra Johann1,2 and Ulrike Ehlert1*
Abstract
Background: Postpartum depression is considered to be one of the most common health threats during pregnancy
and postpartum, affecting not only the woman herself but also the offspring and the whole family system. Evidence for a
conclusive etiopathological model with distinct risk and resilience factors is still broadly lacking. Therefore, the aim of the
present study is to investigate numerous health-related markers to obtain greater insight into which biopsychosocial
profiles render women more vulnerable to PPD or facilitate a healthy transition from pregnancy to postpartum.
Methods: The observational, longitudinal study aims to include a total of 288 physically healthy women, aged
20–45 years. A multitude of relevant parameters, of an (epi-) genetic, endocrinological, physiological and
psychological nature, will be assessed over a period of 5 months, following the participants from the 3rd
trimester until three months postpartum.
Discussion: The ultimate goal of the present study is to ameliorate mental health care during pregnancy and
postpartum, by gaining a better understanding of the underlying biopsychosocial mechanisms that women
undergo during the transition from pregnancy to postpartum.
Keywords: Pregnancy, Postpartum, Stress, Depression, Steroid hormones, Psychophysiology
Background
Depression is projected to become the leading contributor
to the global burden of disease worldwide by 2030 [1]. It
causes severe impairments to quality of life, and the ad-
verse effects often extend to the whole family system of
the affected individual [2]. For instance, maternal
depression is associated with unfavorable neonatal birth
outcomes, and the offspring can show an up to threefold
increased risk of developing a depressive disorder
throughout later life [3, 4]. It is well known that women’s
lifetime risk of suffering from major depression is twice as
high as that of men [5]. This sex difference emerges dur-
ing early adolescence and leads to a lifetime prevalence of
16.5–21.7% for women in the US and Europe, compared
to 8.9–12.7% for men [6, 7].
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Even though pregnancy and childbirth mark a period
filled with joy and excitement for most women, there is
a substantial group of women who are prone to develop
mood disturbances throughout pregnancy and the post-
partum period. As such, the transition phase from preg-
nancy to postpartum depicts an exceptionally vulnerable
phase in a woman’s reproductive life, given prevalence
rates of 10–20% for peri- and postpartum depression [8].
Previous research, including recent work by our own
group, points to different trajectories of the onset and de-
velopment of depressive symptoms during pregnancy and
postpartum [9]. In a large, community-based longitudinal
online survey (N = 687), we found a remarkably high inci-
dence of antenatal and postpartum depressive symptoms
(9.2% and 6.3%, respectively) as well as recurrence rates
(9.2% and 4.1%, respectively) in healthy women and
women with prior depression. It is well established that
women with a history of non-puerperal depression show a
greater risk of developing depressive symptoms during
pregnancy and postpartum [8]. To our knowledge, the
aforementioned study was the first in a large Swiss sample
to clearly differentiate between recurrent and de novo epi-
sodes of depressive symptoms in pregnancy and postpar-
tum. As such, we assume that there might be distinct
biopsychosocial profiles, following different etiopathologi-
cal pathways, which render some women more vulnerable
to depression during pregnancy and postpartum com-
pared to women who remain mentally healthy throughout
the peripartum period.
Potential mechanisms that render these women more
vulnerable might be found in the reported stress-
provoked dysregulation of the HPA axis linked to non-
puerperal depression [10]. In line with these findings,
higher placental corticotropin-releasing hormone (pCRH)
levels in mid to late pregnancy have been found to be a
strong predictor of postpartum depression (PPD) [11]. A
potential explanation may be that the prolonged elevation
of pCRH in pregnancy leads to greater residual hypothal-
amic suppression and HPA axis hypoactivity in women
after giving birth [12]. Therefore, women with prior non-
puerperal depression might show a phenotype of greater
vulnerability to the substantial changes of the HPA axis
during pregnancy and postpartum.
A further, hormone-sensitive phenotype has been dis-
cussed in previous research in women with a history of
premenstrual syndrome/premenstrual dysphoric disorder
or prior PPD. These women show a greater risk of devel-
oping depressive symptoms during pregnancy and post-
partum [13]. Sex steroids rise exponentially during
pregnancy, with a sharp drop following delivery and the
associated displacement of the placenta [14]. The rapid
withdrawal of sex steroids can also be found in other re-
productive phases, for example the luteal phase of the
menstrual cycle or the perimenopause in later life. It has
been shown that some women react particularly sensi-
tively to sudden withdrawal and fluctuations of estrogen
and progesterone, resulting in mood disturbances [15, 16].
A notable key player associated with postpartum depres-
sion might also be one of the metabolites of progesterone,
allopregnanolone: Lower rates in the second and third tri-
mester have been linked to an elevated risk of PPD [17].
Women prone to hormonal sensitivity are also more likely
to experience somatization; for instance, hot flushes have
been associated with depressive symptoms during preg-
nancy and in the postpartum period [18].
There is an additional group of women who may show
symptoms of depression during pregnancy but find
themselves in remission after giving birth. These women
might show greater physiological, psychological and psy-
chosocial resources and resilience.
Specific genetic predispositions and epigenetic
mechanisms seem to influence the likelihood of suf-
fering from mood disturbances during pregnancy and
postpartum, and might even differentiate between
women with a history of non-puerperal depression
versus women with prior PMS/PPD on a (epi-) gen-
etic level. In non-puerperal and peripartum depres-
sion, polymorphisms of the glucocorticoid receptor
gene (GR1), the CRH receptor 1 (CRHR1), the short
version of the serotonin transporter-linked poly-
morphic region genotype (5-HTTLPR), as well as the
serotonin 2A receptor (HTR2A) and protein kinase C
(PRKCB) have been found [19–23]. Distinct bio-
markers for PPD focus on polymorphisms that impli-
cate reproductive hormones, e.g. in the estrogen
receptor alpha gene, and suggest an enhanced sensi-
tivity to estrogen-based DNA methylation reprogram-
ming [24]. In one study, the development of PPD was
predicted with an accuracy of 88% in women with a
higher expression change in response to ERα signaling
[25]. Research regarding the epigenetic mechanisms of
the G protein-coupled estrogen receptor gene 1 is still
lacking. So far, despite extensive research, evidence
for a conclusive etiological model for PPD, including
potentially distinct biopsychosocial profiles and phe-
notypes, is largely absent, most likely due to the lack
of combined assessments of biopsychosocial markers
relevant for pregnancy and the postpartum period.
The present study proposes an integrative etiopatholo-
gical model with distinct trajectories including (epi-)
genetic vulnerability, chronic stress or adverse life
events, which result in a potential dysregulation of the
HPA and HPG axis and their counter-regulation and
render some women more sensitive to the fluctuations
of sex steroids throughout pregnancy and the postpar-
tum period.
As such, the study seeks to provide an etiopathological
model that contributes to explaining the higher
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prevalence of depressive disorders in women, with the
ultimate aim of improving prevention, diagnosis and
treatment of peri- and postpartum depression.
Methods/design
Design
The present study will be an observational, longitudinal,
single-center, national study. Data will be collected be-
tween June 2019 and potentially December 2020, de-
pending on the current situation regarding Covid-19.
Pregnant women interested in participating will be
screened for eligibility using both 1) an online tool to
screen for current depressive symptoms and prior de-
pression with a short questionnaire using validated cut-
off scores, and 2) a telephone interview to verify the in-
clusion criteria. Before completing the screening ques-
tionnaire, potential participants will be presented, on an
online platform, with the inclusion criteria for study par-
ticipation, general information about participation and a
declaration of consent for the screening. Potential partic-
ipants will also be provided with a privacy statement,
which refers to the relevant privacy aspects of the
screening and the online surveys, and to which they
must also explicitly agree. The online screening will
compromise an examination of the general inclusion
and exclusion criteria of the study, the Edinburgh Post-
natal Depression Scale (EPDS) and an assessment of
prior depressive episodes according to DSM-5 criteria. If
the inclusion criteria will be met, participants will be in-
vited to the first of two appointments at the laboratory
(lab visit 1) between 34 and 36 weeks of gestation (3rd
trimester of pregnancy).
All lab appointments will take place at the lab of the
Institute of Psychology at the University of Zurich. Dur-
ing these visits, sociodemographic as well as health- and
pregnancy-related information will be obtained. Add-
itionally, the women will respond to psychological self-
report questionnaires (see Table 1). As part of the lab
visits, participants will undergo the Screening for the
Structured Clinical Interview for DSM-IV (SCID-DSM-
IV). If necessary, this will be followed by the SCID-IV
interview, conducted by a trained clinical psychologist.
During both laboratory visits, capillary blood samples
(dried blood spots) will be taken from the fingertip using
Table 1 Self-report questionnaires
Construct Assessment instrument Authors Items
Postpartum Depression Edinburgh Postnatal Depression Scale (EPDS) Cox, J. L., Holden, J. M., & Sagovsky, R., 1987 10
Prenatal stress Prenatal Distress Questionnaire (PDQ) Yali & Lobel, 1999; Pluess et al., 2010 12
Premenstrual syndrome German Version PMS-Questionnaire Ditzen et al., 2011 30
Reproductive aging Menopause Rating Scale (MRS II) Hauser, Schneider, Rosemeier & Potthoff, 1999 11
Anxiety State-Trait Anxiety Inventory Short Version (STAI-SKD) Englert, Bertrams & Dickhäuser, 2011 5
Stress, Sleep Visual analog scales (VAS) Klinkenberg et al., 2009 5
Anxiety State-Trait Anxiety (STAI-X) Laux, Glanzmann, Schaffner & Speilberger 20
Neuroticism NEO Big Five Short Version Körner et al., 2008 6
Childhood Traumatic Experiences German Version Childhood Trauma Screener (CTS) Grabe et al., 2012 5
Life events German Version Life Experience Survey (LES) Sarason et al., 1978; Pluess et al., 2010 55
Self-esteem Rosenberg Self-esteem Scale (SES) Collani & Herzberg 10
Daily hassles ZIPS Subscale (Daily Uplifts) Bratsikas, Mohiyeddini, Viecelli & Ehlert, submitted 10
Maternal-fetal attachment Maternal fetal attachment scale (MAFS) Cranley, 1981; Sjörgen et al., 2004 17
Relationship quality Couples Satisfaction Index Funk & Rogge, 2007 4
Social support Berlin Social Support Scales (BSSS) Schulz & Schwarzer, 2000 17
Traumatic experiences Lifetime German Version Trauma History Questionnaire Green, 1996; Maercker & Bromberger, 2005 24
Birth Anxiety Birth Anxiety Scale (GAS) Short Version Lukesch, 1983 25
Perfectionism Multidimensional Perfectionism Scale (MPS) Altstötter, Gleich & Bergemann, 2006 35
Impact of Events Impact of Event Scale (IES) Horowitz Stadlmayr, Cignacco, Surbek, Büchi 15
Mother-baby interaction The mother and baby interaction scale Hovik et al., 2013 9
Chronic stress Trier Inventory for Chronic Stress, Short Version (TICS-K) Schulz, Scholz & Becker, 2004 39
Emotions towards motherhood LIWC2015_Language Manual Pennebaker et al., 2015 1
Maternal-fetal Attachment Pictorial Representation of Attachment (PRAM) Van Bakel et al., 2013 3
Emotional support Maternal adjustment five months after birth Lemola et al., 2007 7
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a lancet (Accu-Chek Safe-T-Pro Plus), based on the
model of blood glucose measurement in diabetic pa-
tients. The blood spots will be absorbed by a special fil-
ter paper (Whatman 903) and dried for 3–4 hours at
room temperature before being stored. In addition, per-
ipheral physiological measures (blood pressure) will be
taken at both laboratory appointments. At the end of the
first lab visit, all women will receive a study material
package and both oral and written instructions on how
to collect the study parameters on their own.
Following lab visit 1, the pregnant women will be asked
to provide saliva samples and to complete short question-
naires regarding perceived stress, quality of sleep and
mood state on two consecutive weekdays between 34 + 0
and 36 + 0 weeks gestation, and then again as close to the
due date as possible (i.e., 40 weeks gestation) in order to
capture the steep hormone increase as close to delivery as
possible. On the evening before sampling, the women will
receive a reminder by email. In total, each participant will
collect 32 saliva samples (using Salicaps, IBL) at home, on
two consecutive weekdays at 34–36 weeks of gestation, at
40 weeks of gestation, at 4–8 weeks PP, and at 8–12 weeks
PP (T1- immediately after awakening; T2–30 min after
awakening; T3–45 min after awakening; T4 - in the even-
ing). The women will additionally wear a smart sensor
bracelet to collect psychophysiological data during the
days of saliva sampling.
At 8–12 weeks postpartum, the women will be invited
to a second and final lab visit (lab visit 2). The procedure
of the second visit will be comparable to the first (i.e.,
SCID Screening, dried blood spot sampling, measurement
of psychological and psychophysiological parameters).
Additionally, birth- and postpartum-specific information
will be obtained. All women will be compensated with gift
vouchers as well as maternity and infant care products (in
total worth approximately CHF 150.-). Moreover, the
women will receive a summary of all major research find-
ings. An overview of the study design can be found in
Fig. 1.
Sample
The study will include a total of 288 physically healthy
pregnant women aged between 20 and 45 years. Both
women who were mentally healthy prior to pregnancy
and women with a history of depression according to
DSM-5 will be eligible for participation. The women will
Fig. 1 Study design. t1=34-36 weeks;t2=40 weeks;t3=1-5 days postpartum;t4=4-8 weeks; postpartum;t5=8-12 weeks postpartum
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be examined beginning from the 3rd trimester of preg-
nancy onwards and followed into the postpartum period
8–12 weeks after giving birth.
The following exclusion criteria will be applied: multi-
fetal gestation; pregnancies achieved through assisted re-
productive technology; medical complications (e.g.,
hypertension, diabetes mellitus, hyperemesis gravidarum,
(pre)eclampsia, suspected fetal growth restriction, fetal
structural abnormalities); medical condition or surgical
intervention that might have affected ovarian function
prior to pregnancy or may affect ovarian function during
the postpartum period (e.g., polycystic ovary syndrome,
endometriosis, breast cancers); current or past history of
psychosis, bipolar disorder, posttraumatic stress dis-
order, eating disorder, substance abuse or dependency;
current intake of hormones (e.g., corticosteroids), di-
uretics, hypertensives, vasodilators; treatment with psy-
chotropic substances within the last 3 months preceding
study inclusion; drug use and/or smoking; alcohol intake
of more than one standard unit a day; pre-pregnancy
body mass index (BMI) > 25 or < 18; protein-restricted
diet, and/or regular consumption of soy products.
For the sample size estimation, we performed an a
priori sample size estimation analysis using GPower 3.1
[26]. The analysis was computed taking a middle effect
size of 0.25 with α = 0.05 and power = 0.95 (1-β a) into
account. Since only pregnant women who will give birth
to a healthy child will be included into the statistical
analyses, and in order to take a drop-out rate of approxi-
mately 10% into account, a sample size of N = 288 was
estimated to obtain comparable subgroups of women
with/without prior depression and with/without PPD ac-
cording to recent prevalence rates.
Enrollment/informed consent
Recruitment began directly after approval of the pro-
posal by the Ethics Committee of the Canton of Zurich,
Switzerland. Data of the 288 study participants will be
collected continuously for 30 months. Information about
the study will be published on the research team’s web-
site, www.ichbinschwanger.ch, which was developed
seven years ago with the goal of providing pregnant
women with helpful material and knowledge about the
current state of research on psychobiological health dur-
ing pregnancy. Study information leaflets will be handed
out to all pregnant women receiving prenatal medical
care at the obstetric departments of all major outpatient
clinics of hospitals in and around Zurich, Switzerland.
The study information leaflets will also be placed in as
many outpatient clinics for gynecology and obstetrics in
the Zurich area as possible, and will be handed out to
midwives and antenatal classes. Additionally, study in-
formation leaflets will be offered to pregnant women vis-
iting psychosocial counseling institutions regarding
pregnancy and birth. Moreover, recruitment will also be
conducted via various mailing lists, online and news-
paper advertisements, specific offers for pregnant
women (e.g. prenatal yoga) and social media (e.g. Face-
book). Informed consent will be first obtained electron-
ically for the online screening tool, and written informed
consent will be obtained prior to any data collection.
Outcome measures
Psychological measures, sociodemographic characteristics
and pregnancy-specific parameters
In order to measure relevant psychological parameters,
the participants will complete validated German versions
of questionnaires regarding the following clusters of var-
iables: psychological state and trait variables such as anx-
iety, depression and stress; potential risk factors such as
early trauma and adverse life events; potential protective
factors such as relationship quality; sociodemographic
characteristics; and health-, pregnancy-, and birth-
specific characteristics. Online data will be collected
using the Unipark platform (www.unipark.com/de, cer-
tificate ISO 27,001), which is reliably protected from any
external access. The BSI-certified data center is subject
to requirements of high data protection and safety in
conformity with ISO 27,001 based on the IT basic pro-
tection. A comprehensive overview of all self-report
questionnaires can be found in Table 1.
Neuroendocrine parameters
Neuroendocrine parameters will be measured using sal-
iva and dried blood spot sampling, with blood obtained
from finger prick. With regard to saliva, the HPG hor-
mones of interest will include salivary E, P, and ALLO.
Salivary cortisol, the end product of the HPA axis, will
also be analyzed.
Saliva samples will be collected via Salicaps (a passive
drooling device; IBL International GMBH, Hamburg,
Germany). Salivary E, P, and cortisol concentrations will
be quantified by luminescence immunoassay with com-
mercial immunoassay kits (IBL-Hamburg, Germany).
Analyses will be conducted in our own laboratory.
ALLO will be analyzed from the first measurement time
point at morning awakening using an enzyme-linked im-
munosorbent assay (ELISA).
Blood samples will be collected through finger prick.
The participants’ finger will be pricked with a sterile,
disposable lancet (commonly used by diabetics, Accu-
Chek Safe-T-Pro Plus), and up to five drops of blood
(about 50 µL per drop) will be spotted onto standardized
filter paper (no. 903 Whatman, DBS Protein Saver Card).
Serotonin and CRH will be assessed from dried blood
samples obtained during lab visit 1 and kept at − 20 °C
until analysis [27, 12]. GABA, LH, and FSH will be mea-
sured in dried blood spots collected during lab visits 1
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and 2 [28]. The filter paper samples will be air-dried
after collection and stored in an airtight plastic bag at −
20 °C until analysis. Biochemical analyses will be con-
ducted at our own laboratory and the Cytolab laboratory
in Regensdorf, Switzerland. An overview of the assessed
biological parameters can be found in Table 2.
Genetic and epigenetic parameters
Methylation will be assessed using an established Next
Generation Sequencing (NGS) method: medium
throughput bisulfite sequencing [29], which has been
previously used by our research group in close cooper-
ation with the lab of Prof. Dr. Turecki, McGill Univer-
sity, Canada. The assay (e.g., primer design) for the
methylation analyses of the NR3C1, FKBP5, ERα, ERβ,
and GPER are already established in the lab, while the
assay development for the CRHR1 gene is currently on-
going and will be fully operational by the projected time
of analysis.
TagSNPs selected in the candidate genes, according to
the previously reported TagSNPs selection procedure
[30], and SNPs showing evidence of association, will be
included in a custom genotyping array and analyzed at
the Genetic Diversity Center (GDC), ETH, Zurich. Vari-
able length tandem repeats (VNTRs) will be analyzed by
polymerase chain reaction (PCR) followed by capillary
electrophoresis [31].
Psychophysiological parameters
To assess relevant psychophysiological data, participants
will wear a smart sensor bracelet, the Everion CD, devel-
oped by the medical technology company Biovotion
(https://www.biovotion.com). The Everion CD is a non-
invasive physiological monitor that is CE-certified as a
class IIa medical device. It provides 22 parameters and
features measured in very short intervals (every second)
with medical-grade quality. Measured psychophysio-
logical parameters that are influenced by both the HPG
and HPA axis hormones include the following: heart rate
(HR), heart rate variability (HRV), resting respiratory
rate (RR), skin temperature, electrodermal activity
(EDA), skin blood perfusion, steps, activity, barometric
pressure, blood pulse wave, and blood oxygen saturation.
The large collected dataset will permit us to address
multiple research questions, such as associations be-
tween perceived sleep quality, objective amount of sleep,
and the development of PPD. Additionally, the sensor
bracelet will be able to track participants’ sleep duration
and awakening time, which is essential for the statistical
analyses and interpretation of the morning awakening
response [32]. These data will be transferred to a smart-
phone app, which the women will download and install
on their smartphone upon study enrollment. Besides big
data analyses in cooperation with the mobile devices
center of the URPP Healthy Aging, the collected data
Table 2 Biological parameters
Source Label Parameter








- Corticotropin-releasing hormone (CRH)






Blood pressure Periphysiological parameter - blood pressure
Everion CD - bracelet Psychophysiological parameter - heart rate
- heart rate variability
- skin blood perfusion






- blood oxygen saturation
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will be investigated with specific algorithms provided by
Biovotion. For data security, each woman will receive a
unique identification code. Biovotion handles customer
data in compliance with the GDPR. Finally, participants’
blood pressure will be assessed during the two lab visits in
order to control for cardiovascular parameters in addition
to the measurements with the Everion CD bracelet.
Statistical analysis
The statistical analyses will be conducted using the Stat-
istical Package for the Social Sciences (SPSS 22.0,
Armonk, NY, USA) and the open-source software R (the
R Foundation for Statistical Computing, Vienna, Austria)
amongst others. Multivariate analyses of variance, multi-
variate regression analyses, cluster analyses, multilevel/
mixed models, and mediator and moderator analyses will
be used to analyze the neuroendocrine, psychological,
(epi-) genetic and physiological parameters [33, 34].
Hypothesis-free data-mining approaches will be used to
analyze the large amounts of data collected via the smart
sensor bracelet in combination with the repeatedly
assessed neuroendocrine and psychological parameters
[35]. With these analyses, the associations between bio-
rhythms and depressive symptoms will be explored. To
minimize the risk of over-interpreting incidental findings,
split-half procedures will be used to compare hypothesis-
driven analyses with data-mining models [36]. Moreover,
all statistical analyses will be corrected for multiple testing
as appropriate. The two-sided significance level will be set
at p < .05. The study population will be homogenous in
terms of pregnancy/PP status (from 34 to 36 weeks of
pregnancy until 8–12 weeks PP).
Study status
From June 2019 to March 2020, a total of 659 women
expressed an interest in participating by clicking on the
online screening questionnaire, and 150 (22.8%) women
completed the online screening questionnaire. After re-
assessment of the inclusion criteria by telephone, 101
(15.3%) participants were found to be eligible for the
Fig. 2 Sample inclusion
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study, until a recruitment halt due to Covid-19. Until
March 2020, 18 (17.8%) women were reported as drop-
outs, mostly because of pregnancy- or postpartum-
related medical complications. An overview of the inclu-
sion process can be found in Fig. 2.
Discussion
The present study aims to provide further insight into
the etiopathological mechanisms that render some
women more vulnerable to mood disturbances and anx-
iety throughout pregnancy and the postpartum period.
To the best of our knowledge, previous research has
mostly focused on either biological or psychological fac-
tors, whereas a comprehensive investigation of all rele-
vant factors is still lacking. The main goal is to assess
and evaluate specific health-related markers, such as
(epi-) genetic factors, hormonal patterns, and psycho-
social and physiological parameters that contribute to a
healthy transition or maladaptation from pregnancy to
postpartum.
Given the prevalence rates and multiple possible nega-
tive outcomes for the affected individual and the whole
family system, it is of utmost importance to gain deeper
insight into the underlying mechanisms of PPD. Previous
research has pointed in the direction of possibly different
trajectories, meaning that not all women are affected
equally by the same hormonal changes or risk factors.
Therefore, this study aims to find not only an overall
etiopathological model, but also different trajectories of
PPD, consisting of specific subgroups of vulnerable
women who show a distinct biopsychosocial profile. The
strengths of the present study design lie in its longitu-
dinal nature, the application of strict inclusion criteria
and the large set of relevant markers being assessed. A
further strength is the inclusion of women with prior de-
pression, women with current depression and/or anxiety,
and mentally healthy women, which will enable us to
follow up different pathways and their underlying mech-
anisms during pregnancy and the postpartum period.
Since distinct (epi-) genetic markers of PPD are still
largely missing, we hope to obtain greater insight into
possibly relevant gene-environment interactions regard-
ing PPD. To gain objective physiological data, we will
use smart sensor bracelets in order to monitor physio-
logical symptoms in addition to self-assessment ques-
tionnaires (e.g. regarding sleep and stress). In
conclusion, the present study aims to fill the gap in
terms of achieving a conclusive etiopathological model
regarding PPD by assessing numerous relevant biopsy-
chosocial parameters in a longitudinal design and large
sample. This should ultimately enable us to distinguish
which women tend to have a high risk for mood distur-
bances during pregnancy and the postpartum period and
thereby enhance prevention, diagnosis and treatment of
PPD.
Limitations
So far, no declarations can be made, since the study is
still ongoing.
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